NCT05905146 Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.
| NCT ID | NCT05905146 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Rouen |
| Condition | Acute Pathology of the Locomotor System |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-01-18 |
| Primary Completion | 2028-07-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-01-18 with a primary completion date of 2028-07-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.
Eligibility Criteria
Inclusion Criteria: * Patient hospitalized in the rheumatology department * Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology * Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion Exclusion Criteria: * Patient with cancer or fibromyalgia already diagnosed at inclusion * Patient with poor French language skills * Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion * Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment * Patient already included in the study
Contact & Investigator
Catherine CHENAILLER
PRINCIPAL INVESTIGATOR
University Hospital, Rouen
Frequently Asked Questions
Who can join the NCT05905146 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Pathology of the Locomotor System. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05905146 currently recruiting?
Yes, NCT05905146 is actively recruiting participants. Contact the research team at catherine.chenailler@chu-rouen.fr for enrollment information.
Where is the NCT05905146 trial being conducted?
This trial is being conducted at Lille, France, Nîmes, France, Rouen, France.
Who is sponsoring the NCT05905146 clinical trial?
NCT05905146 is sponsored by University Hospital, Rouen. The principal investigator is Catherine CHENAILLER at University Hospital, Rouen. The trial plans to enroll 200 participants.